AMGN · Amgen Inc.
$347.942026-05-17Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$285
-18.0% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($285 · $589) Analysts Range ($185 · $432) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $26.0B | — | 37.0% | 12.1% | $8.5B | −$3.8B | $4.7B | 4.1% | — | 17.6% | $48.0B | $10.85 | — |
| 2022.Q4 | $26.3B | 1.3% | 45.8% | 10.8% | $10.7B | −$3.7B | $7.1B | 5.8% | — | 23.2% | $44.5B | $12.07 | — |
| 2023.Q4 | $28.2B | 7.1% | 35.3% | 14.5% | $8.5B | −$26.3B | −$17.8B | 5.8% | — | 14.6% | $72.0B | $12.37 | — |
| 2024.Q4 | $33.4B | 18.6% | 27.4% | 11.3% | $8.1B | $4.6B | $12.7B | 6.7% | — | 11.5% | $69.1B | $7.53 | — |
| 2025.Q4 | $36.8B | 10.0% | 35.3% | 14.1% | $11.1B | −$1.5B | $9.6B | 6.2% | — | 15.8% | $71.8B | $14.20 | 14.6 |
| italics below = DCF projection · 10yr Rev CAGR: 3.6% |
| 2026.Q4 | $37.8B | +2.9% | 37.0% | 14.7% | $11.9B | −$3.5B | $8.5B | 6.5% | $8.0B | 16.2% | $75.3B | $17.46 | 19.9 |
| 2027.Q4 | $39.0B | +3.0% | 37.6% | 15.3% | $12.4B | −$3.1B | $9.4B | 6.7% | $8.3B | 16.2% | $78.3B | $18.18 | 19.1 |
| 2028.Q4 | $40.2B | +3.2% | 40.8% | 15.9% | $13.8B | −$2.8B | $11.0B | 6.9% | $9.1B | 17.3% | $81.1B | $20.18 | 17.2 |
| 2029.Q4 | $41.9B | +4.1% | 39.0% | 16.5% | $13.6B | −$3.7B | $9.9B | 7.1% | $7.6B | 16.4% | $84.8B | $19.92 | 17.5 |
| 2030.Q4 | $43.3B | +3.4% | 39.0% | 17.1% | $14.0B | −$3.3B | $10.7B | 7.3% | $7.6B | 16.2% | $88.2B | $20.46 | 17.0 |
|
| Term. Yr+ | $54.4B | 4.1% | 34.8% | 20.0% | $15.1B | −$4.7B | $10.4B | 8.6% | $112.8B | 13.1% | — | — | — |
Active scenario IV: $285 (-18.0% vs market)